Replimune Group (NASDAQ:REPL) Given Neutral Rating at Wedbush

Wedbush reiterated their neutral rating on shares of Replimune Group (NASDAQ:REPL) in a report issued on Monday, Marketbeat reports. Wedbush currently has a $2.00 target price on the stock, down from their previous target price of $19.00.

A number of other research firms have also recently issued reports on REPL. Piper Sandler cut shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target on the stock. in a research note on Friday. JPMorgan Chase & Co. restated an “underweight” rating on shares of Replimune Group in a report on Monday. HC Wainwright restated a “sell” rating on shares of Replimune Group in a report on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. Six analysts have rated the stock with a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $4.63.

Replimune Group Price Performance

Replimune Group stock opened at $1.70 on Monday. The company’s fifty day moving average price is $7.41 and its 200 day moving average price is $7.94. Replimune Group has a 1 year low of $1.50 and a 1 year high of $13.24. The stock has a market capitalization of $140.37 million, a P/E ratio of -0.49 and a beta of 0.74. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.08. As a group, equities research analysts anticipate that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insider Activity at Replimune Group

In other news, insider Christopher Sarchi sold 6,500 shares of Replimune Group stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total transaction of $52,065.00. Following the transaction, the insider owned 151,588 shares in the company, valued at $1,214,219.88. The trade was a 4.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. International Assets Investment Management LLC purchased a new position in shares of Replimune Group during the 4th quarter worth $29,000. Russell Investments Group Ltd. raised its holdings in shares of Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after acquiring an additional 7,569 shares during the period. CWM LLC raised its holdings in shares of Replimune Group by 248.6% during the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after acquiring an additional 2,886 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Replimune Group by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after acquiring an additional 6,873 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in shares of Replimune Group during the 2nd quarter worth $69,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

More Replimune Group News

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Company response — Replimune’s executive chairman publicly called the FDA decision “unfair” and discussed next steps in a TV interview; management tone suggests they will contest or seek clarification with the agency. Replimune co-founder calls FDA rejection ‘unfair’
• Neutral Sentiment: Market mechanics — Trading on REPL was temporarily halted (LULD pause) during the sell-off as the market digested the CRL. (Intraday regulatory pause)
• Neutral Sentiment: Industry analysis — A PharmTech piece reviews lessons from the RP1 CRL for other developers; useful context but does not change Replimune’s immediate financials. What Pharma Developers Can Learn From RP1’s Rejection
• Negative Sentiment: Regulatory setback — The FDA issued a CRL for RP1’s Biologics License Application for advanced melanoma, delaying approval and forcing Replimune to address agency deficiencies before any potential approval. FDA Issues CRL to Replimune for RP1 BLA
• Negative Sentiment: Second CRL / program risk — Coverage notes this is a second CRL for RP1, increasing uncertainty about the regulatory path and timing for any approval or label; that uncertainty undermines near-term revenue and valuation expectations. Replimune Gets Second FDA CRL
• Negative Sentiment: Market reaction — Major outlets report REPL plunged to an all-time low on the news, with heavy trading and a dramatic drop in market value. Street sours on Replimune
• Negative Sentiment: Cost actions — Reports indicate Replimune is planning layoffs after the FDA decision, signaling management expects reduced near-term operating activity and is cutting burn. Replimune plans layoffs after FDA rejects cancer therapy
• Negative Sentiment: Analyst reaction — Multiple firms cut ratings and slashed price targets (downgrades and lower PTs from Jefferies, BMO, Wedbush, Leerink, JPMorgan, HC Wainwright, Piper and others), reflecting reduced probability of near-term upside. FDA Rejection Sparks Questions On Replimune Drug Approval Path

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.